Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation.

This document summarizes a study on the outcomes of patients with mantle cell lymphoma (MCL) who received different treatments. The study found that the overall survival rates at two and four years were 91% and 68% respectively. Patients who received rituximab maintenance therapy had higher survival rates compared to those who did not. The blastoid variant of MCL was associated with lower survival rates. The study also found that autologous hematopoietic stem cell transplant (HSCT) in an outpatient setting was safe and effective. Overall, the study suggests that the best available care, including rituximab maintenance therapy and HSCT, should be provided for MCL patients. [Extracted from the article]